Consumables was Standard Biotools’s largest product and service line in fiscal 2025, bringing in $36.25M of $85.33M (42%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Consumables | $46.79M | $41.74M | $40.54M | $36.25M | ||||||
| Instruments | $25.66M | $37.46M | $24.89M | $25.41M | ||||||
| Service & Other Revenue | — | $27.14M | $25.58M | $23.67M | ||||||
| Instrument Support Services | $23.22M | — | — | — | ||||||
| Service Revenue | — | — | — | — | ||||||
| Development Revenue | — | — | — | — | ||||||
| Grant Revenue | — | — | — | — | ||||||
| Collaboration & Other Revenue | $1.78M | — | — | — | ||||||
| License | — | — | — | — | ||||||
| Other Revenue | — | — | — | — | ||||||
| License Revenue | — | — | — | — | ||||||
| Assay Services | $493.00K | — | — | — | ||||||
| Total | $97.95M | $106.34M | $91.01M | $85.33M |
Standard Biotools brought in $85.33M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 6.2% from $91.01M in fiscal 2024. Consumables was the largest at $36.25M (42.5%), ahead of Instruments at $25.41M (29.8%) and Service & Other Revenue at $23.67M (27.7%).
Compared with fiscal 2024, Instruments grew fastest, up 2.1% to $25.41M, while Consumables fell the most, down 10.6% to $36.25M.
Standard Biotools began breaking out Service & Other Revenue in fiscal 2023, when it brought in $27.14M. Standard Biotools stopped reporting Instrument Support Services ($23.22M in fiscal 2022), Collaboration & Other Revenue ($1.78M in fiscal 2022) and Assay Services ($493.00K in fiscal 2022) as separate lines.
Emea was Standard Biotools’s largest region in fiscal 2025, bringing in $35.99M of $85.33M (42%).
| Geography | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $43.98M | $46.20M | $37.40M | $30.56M | ||||||
| Emea | $33.14M | $36.20M | $35.65M | $35.99M | ||||||
| Asia-Pacific | $20.83M | $23.94M | $17.96M | $18.78M | ||||||
| Total | $97.95M | $106.34M | $91.01M | $85.33M |
Standard Biotools brought in $85.33M from its three regions in fiscal 2025, the year ended December 31, 2025. That was down 6.2% from $91.01M in fiscal 2024. Emea was the largest at $35.99M (42.2%), ahead of Americas at $30.56M (35.8%) and Asia-Pacific at $18.78M (22.0%).
Compared with fiscal 2024, Asia-Pacific grew fastest, up 4.6% to $18.78M, while Americas fell the most, down 18.3% to $30.56M. From fiscal 2022 to 2025, combined revenue from these regions fell from $97.95M to $85.33M, a compound annual decline of 4.5%. Emea's share of the total rose from 33.8% to 42.2%.
Proteomics was Standard Biotools’s largest segment in fiscal 2022, bringing in $52.50M of $97.95M (54%).
| Segment | FY 2021 | FY 2022 |
|---|---|---|
| Proteomics | $67.66M | $52.50M |
| Genomics | $62.92M | $45.45M |
| Total | $130.58M | $97.95M |
Standard Biotools brought in $97.95M from its two segments in fiscal 2022, the year ended December 31, 2022. That was down 25.0% from $130.58M in fiscal 2021. Proteomics was the largest at $52.50M (53.6%), ahead of Genomics at $45.45M (46.4%).
Compared with fiscal 2021, Proteomics fell 22.4% to $52.50M and Genomics fell 27.8% to $45.45M.
Standard Biotools (LAB) reports its revenue by product and service, by geography and by segment. In fiscal 2025, Consumables was its largest product and service line, bringing in $36.25M (42.5% of the total), followed by Instruments at $25.41M (29.8%).
Consumables was Standard Biotools' largest product and service line in fiscal 2025, bringing in $36.25M, or 42.5% of the $85.33M total across its three product and service lines.
Emea was Standard Biotools' largest region in fiscal 2025, bringing in $35.99M, or 42.2% of the $85.33M total across its three regions.
Proteomics was Standard Biotools' largest segment in fiscal 2022, bringing in $52.50M, or 53.6% of the $97.95M total across its two segments.
Among Standard Biotools' product and service lines that make up at least 2% of revenue, Instruments grew fastest in fiscal 2025, up 2.1% from $24.89M to $25.41M.
Every figure comes from Standard Biotools' annual financial filings, as reported. Each line keeps the name Standard Biotools gives it, and years follow its fiscal calendar.
Standard Biotools' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.